[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Saxena A, Memauri B, Hasegawa W: Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour. J Clin Pathol; 2005 Mar;58(3):331-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour.
  • Warthin tumours (WT) and malignant lymphomas are only rarely associated, and most are examples of involvement of the lymphoid stroma of WT by a disseminated lymphoma.
  • This report describes a case where excision of a parotid mass led to the initial diagnosis of WT and small lymphocytic lymphoma (SLL).
  • The diagnosis of SLL was confirmed by immunohistochemistry and molecular studies.
  • The patient had stage IV A disease and is currently in chemotherapy induced complete remission.
  • [MeSH-major] Adenolymphoma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Jan;113(1):113-9 [10631864.001]
  • [Cites] Histopathology. 1993 Mar;22(3):280-1 [8495960.001]
  • [Cites] Ear Nose Throat J. 1979 Aug;58(8):345-50 [583035.001]
  • [Cites] Pathol Annu. 1979;14 Pt 2:307-24 [583554.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):13-38 [7467121.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2948-50 [7139585.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Hum Pathol. 1985 Apr;16(4):424-7 [3980011.001]
  • [Cites] J Pathol. 1985 Jul;146(3):167-77 [3928854.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):491-6 [3082065.001]
  • [Cites] Pathol Res Pract. 1986 Oct;181(5):615-20 [3786253.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):341-4 [2538052.001]
  • [Cites] Tumori. 1990 Apr 30;76(2):212-5 [2184550.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):974-7 [2394439.001]
  • [Cites] Pathology. 1992 Apr;24(2):60-2 [1322520.001]
  • [Cites] Ear Nose Throat J. 1993 Apr;72(4):264-9, 272-3 [8486105.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • (PMID = 15735173.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770608
  •  go-up   go-down


2. Harish K, Mangala Gouri SR: Adenoid cystic carcinoma of the parotid metastasizing to liver: case report. BMC Cancer; 2004 Jul 30;4:41
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the parotid metastasizing to liver: case report.
  • BACKGROUND: Adenoid cystic carcinoma is a rare malignant parotid tumor.
  • Metastasis can occur even a decade or more after initial treatment of the primary.
  • CASE PRESENTATION: We report a 60 year old female patient who presented with adenoid cystic carcinoma of the parotid gland.
  • While on follow up, patient developed multiple liver metastases which manifested three years later.
  • Palliative chemotherapy can be considered in symptomatic cases while the usefulness of metastasectomy is controversial.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Liver Neoplasms / secondary. Parotid Neoplasms / radiotherapy. Parotid Neoplasms / surgery

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Oct;88(4):473-8 [10519758.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):775-9 [12828706.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • [Cites] Am J Surg. 1974 Oct;128(4):512-20 [4371368.001]
  • [Cites] Am Surg. 1975 Oct;41(10):655-8 [1163909.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):589-90 [6295610.001]
  • [Cites] Cancer Metastasis Rev. 1982;1(1):5-16 [6764375.001]
  • [Cites] Br J Ophthalmol. 1986 Feb;70(2):100-3 [3004556.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] J Oral Pathol Med. 1990 Mar;19(3):101-7 [2160530.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Apr;106(4):332-8 [1314372.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):623-8 [1334380.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1995 Feb;92(2):164-8 [7723170.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):495-8 [9374223.001]
  • [Cites] Surg Neurol. 1998 Nov;50(5):475-9 [9842876.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):216-7 [10390072.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • (PMID = 15285782.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC509249
  •  go-up   go-down


3. Morimoto H, Hashida H, Honda T, Aibara Y: [An elderly case of cytomegalovirus enterocolitis associated with a malignant tumor]. Nihon Ronen Igakkai Zasshi; 2002 Jan;39(1):97-100
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly case of cytomegalovirus enterocolitis associated with a malignant tumor].
  • An 83-year-old man was given a diagnosis of left parotid cancer in our hospital in November 1997.
  • He refused to undergo a surgical procedure because of his advanced age.
  • Therefore chemotherapy and radiotherapy were used.
  • Chemotherapy with CAP (Cyclophosphamide, Adriacin, and CDDP) was conducted on 6 occasions between December 1997 to July 2000.
  • As the patient also began to suffer high grade fevers and stomachaches, he was admitted on a diagnosis of acute enterocolitis.
  • Cytomegalovirus enterocolitis is an opportunistic infection, so immunocompromised hosts (such as cancer patients, patients using immunosuppressants, old people) have a greater probability of contracting cytomegalovirus infection.
  • A ganciclovir is an effective treatment.
  • A cytomegalovirus enterocolitis should considered in the differential diagnosis of enterocolitis, when alimentary symptoms like diarrhea or bloody stool are found in immunocompromised hosts.
  • [MeSH-major] Cytomegalovirus Infections / etiology. Enterocolitis / etiology. Immunocompromised Host. Parotid Neoplasms / immunology
  • [MeSH-minor] Aged. Aged, 80 and over. Antiviral Agents / therapeutic use. Ganciclovir / therapeutic use. Humans. Male

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11857983.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


Advertisement
4. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major salivary gland diseases. Multicentre study.
  • This multicentre study involved 28 Italian ORL Centres responding to a questionnaire sent by us which allowed recruitment of a high large number of cases of parotid neoplasms observed over a 10-year period.
  • Benign tumours account for 80% of case histories with a relationship 1:4 M/F, the most frequent being pleomorphic adenoma (57.3% of cases), followed by Warthin's tumour (32.4%), this rating not having been confirmed in case histories (8-10%) in the literature.
  • Malignant tumours instead were fewer in number compared to the literature (14% vs 25-30%); the most frequent being mucoepidermoid carcinoma (18.2%) of which 44% G1, 33% G2 and 23% G3.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • Enucleoresection was limited to approximately 15% of neoplasms, enucleation to <10% of cases with only 2% of pleomorph adenoma due to the well-known anatomo-pathological characteristics which may lead to relapse.
  • For malignant neoplasms, total parotidectomy was performed in approximately 50% of cases, while in the remaining 50% an almost equal rate of superficial parotidectomy was carried out and enlarged parotidectomy, with or without sacrificing the facial nerve, which was rebuilt in 60% of cases.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • When no clinically evident lymph nodes were present (NO) considering the tumour histotype, two thirds of patients underwent surgery or radiotherapy, while in the remainder the wait-and-see attitude was prefered.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • [MeSH-major] Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


5. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of a second malignancy in a patient with a known malignant tumour is not uncommon.
  • Patient was treated with external beam radiotherapy for carcinoma cervix and breast simultaneously and chemotherapy as required.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • Patient is in regular follow up,having no complain,clinically no neurological dysfunction and no evidence of disease at right parotid and neck region.
  • Thus it was concluded that patients responded well to treatment.
  • Treatment strategies in case of synchronous double malignancy depend on treating the malignancy that is more advanced first or sometimes both could be treated simultaneously.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Treatment Outcome


6. Chao KS, Low DA, Perez CA, Purdy JA: Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer; 2000 Apr 20;90(2):92-103
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience.
  • The purpose of the study was to investigate the feasibility and the optimization of tomotherapy-based intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer.
  • Treatment planning was performed on a Peacock inverse planning system and prescription optimization was used to achieve the best plan for target coverage and parotid sparing.
  • The treatment planning system process has a dosimetric characteristic of delivering different doses to different target structures simultaneously in each daily treatment; therefore, the biological equivalent dose was implemented using the linear-quadratic model to adjust the total dose to the target volume receiving a daily dose of less than 1.9 Gy.
  • All eight patients with gross disease (six in the nasopharynx, two in the tonsil) and one patient with recurrent nasopharyngeal carcinoma received concurrent cisplatin chemotherapy.
  • All patients completed the prescribed treatment without unexpected interruption.
  • To spare the parotid gland, which is in the proximity of the target, a fraction of the target volume may not receive the prescribed dose.
  • In the best-achievable plan of our studied cohort, only 27% +/- 8% of parotid gland volumes were treated to more than 30 Gy, while an average of 3.3% +/- 0.6% of the target volume received less than 95% of the prescribed dose.
  • This is mainly related to the steep dose gradient in the region where the target abuts the parotid gland.
  • The inverse planning system allowed us the freedom of weighting normal tissue-sparing and target coverage to select the best-achievable plan.
  • Local control was achieved in eight patients with gross tumor; six were treated postoperatively.
  • In summary, a system for patient immobilization, setup verification, and dose optimization for head and neck cancer with parotid sparing without significantly compromising target coverage is being implemented for a tomotherapy-based IMRT plan at the Mallinckrodt Institute of Radiology.
  • The initial clinical experience in tumor control is promising, and no severe adverse acute side effects have been observed.
  • Further refining of delivery technology and the inverse planning system, gaining clinical experience to address target definition and dose inhomogeneity within the targets, and understanding the partial volume effect on normal tissue tolerance are needed for IMRT to excel in the treatment of head and neck cancer. Int. J.
  • Cancer (Radiat. Oncol. Invest.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Laryngeal Neoplasms / radiotherapy. Magnetic Resonance Imaging. Middle Aged. Nasopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / radiotherapy. Radiation Dosage. Tonsillar Neoplasms / radiotherapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10814959.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


7. Bouyon A, Hans S, Durdux C, Housset M: [Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?]. Cancer Radiother; 2007 Dec;11(8):465-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?].
  • [Transliterated title] Tumeurs malignes de la parotide: prise en charge multidisciplinaire, rôle de la radiothérapie.
  • The low incidence, the wide histological spectrum and the natural, sometimes slow, evolution of malignant parotid gland tumours do not allow to easily establish the impact of their treatments.
  • We present here the therapeutic highlights of parotid cancers: surgery, with the particular concern of facial nerve preservation; and adjuvant treatment essentially based on radiotherapy.
  • This review focused on adjuvant care explores the indications and the technical aspects of radiation, as well as the role of concurrent chemotherapy.
  • [MeSH-major] Parotid Neoplasms / radiotherapy. Parotid Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy / methods. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888707.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Harish K: Management of primary malignant epithelial parotid tumors. Surg Oncol; 2004 Jul;13(1):7-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary malignant epithelial parotid tumors.
  • Parotid cancers are infrequently encountered.
  • Controversies surrounding pre-treatment evaluation by imaging and fine needle aspiration, utility of operative frozen section are partly resolved.
  • Though surgery remains the mainstay of treatment, radiation is being recognized as a useful adjuvant.
  • The role of chemotherapy is still investigational.
  • The prognosis and necessity of elective neck treatment are mainly guided by the tumor grade and stage.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / therapy. Parotid Neoplasms / therapy
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15145029.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 81
  •  go-up   go-down


9. Perez-Fidalgo JA, Chirivella I, Laforga J, Colio JM, Blanes MD, Baydal R, Roselló S, De-la-Morena E, Lluch A: Parotid gland metastasis of a breast cancer. Clin Transl Oncol; 2007 Apr;9(4):264-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland metastasis of a breast cancer.
  • Parotid gland metastases from malignant tumors are extremely rare.
  • A 61-year-old woman was diagnosed with an early breast cancer with no expression of oestrogen and progesterone receptors.
  • Five years later the patient presented a tumour in parotid gland.
  • After total parotidectomy, microscopic analysis of the gland demonstrated an invasive duct carcinoma (IDC) with positive expression of oestrogen receptor.
  • The patient was treated with chemotherapy followed by complementary local radiotherapy.
  • Diagnosis of a metastasic tumour in parotid gland poses a challenge.
  • In our case an immunohistochemical study of oestrogen receptor was fundamental to establish a diagnosis.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Parotid Neoplasms / secondary
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Immunohistochemistry. Mastectomy, Radical. Middle Aged. Nitriles / administration & dosage. Nitriles / therapeutic use. Parotid Gland / pathology. Parotid Gland / surgery. Receptors, Estrogen / analysis. Time Factors. Treatment Outcome. Triazoles / administration & dosage. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462982.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 0W860991D6 / Deoxycytidine; 2Z07MYW1AZ / anastrozole; 6804DJ8Z9U / Capecitabine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Maier H, Mühlmeier G, Kraft K, Blumstein NM, Tisch M: [Primary malignant melanoma of the parotid gland: a case report and review of the literature]. HNO; 2008 Jun;56(6):627-32
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the parotid gland: a case report and review of the literature].
  • [Transliterated title] Primäres malignes Melanom in der Glandula parotidea: Fallbericht und Literaturübersicht.
  • Malignant melanomas (MMs) of the parotid gland are relatively uncommon.
  • They occur almost invariably as metastases from a primary tumour located in the region of the scalp or the mucous membranes of the nose, paranasal sinuses, or throat.
  • Primary MMs arising in the parotid gland are extremely rare.
  • It is assumed that they originate in the glandular tissue or in intraglandular lymph nodes.
  • We present a case report and review of the literature on the diagnosis, treatment, and prognosis of intraparotid malignant melanoma.
  • Diagnosis is based primarily on B-scan ultrasonography and fine-needle aspiration cytology.
  • Patients with a cytological diagnosis of MM are further evaluated by magnetic resonance imaging and positron emission tomography and receive a thorough ear-nose-throat and dermatological examination.
  • The treatment of choice is total parotidectomy and selective neck dissection.
  • The effectiveness of adjuvant treatments such as radiotherapy, chemotherapy, or immunotherapy remains controversial.
  • Patients with primary MMs of the parotid gland appear to have a better prognosis than those with parotid metastases from melanomas of the skin or mucous membranes.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Parotid Neoplasms / diagnosis. Parotid Neoplasms / therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HNO. 2006 Mar;54(3):166-70 [16091908.001]
  • [Cites] Head Neck. 1997 Oct;19(7):589-94 [9323147.001]
  • [Cites] Laryngoscope. 1994 Oct;104(10):1194-8 [7934587.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1994 Apr;19(2):161-5 [8026097.001]
  • [Cites] Surg Gynecol Obstet. 1963 Sep;117:341-5 [14080349.001]
  • [Cites] Arch Surg. 1997 May;132(5):553-6 [9161401.001]
  • [Cites] Br J Plast Surg. 2001 Oct;54(7):636-7 [11583503.001]
  • [Cites] Am J Surg. 1985 Oct;150(4):510-2 [4051118.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1984 Jan;63(1):17-20 [6700327.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(6):466-9 [11824888.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1961 Jan;14:108-16 [13708292.001]
  • [Cites] Laryngorhinootologie. 2005 Jul;84(7):516-9 [16010634.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Jun;125(6):635-9 [10367919.001]
  • [Cites] Pathol Int. 1997 Aug;47(8):581-3 [9293542.001]
  • [Cites] Br J Oral Maxillofac Surg. 1993 Oct;31(5):313-5 [8218087.001]
  • [Cites] Tumori. 1999 Nov-Dec;85(6):523-5 [10774579.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] Cancer. 2000 Dec 25;90(6):350-6 [11156518.001]
  • [Cites] In Vivo. 1998 Nov-Dec;12(6):571-8 [9891219.001]
  • [Cites] Head Neck. 2001 Sep;23(9):744-8 [11505484.001]
  • [Cites] Arch Surg. 1963 Jul;87:6-12 [14031784.001]
  • [Cites] HNO. 2000 Jun;48(6):421-9 [10929222.001]
  • [Cites] Eur J Surg Oncol. 1990 Feb;16(1):28-32 [2307240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jun;112(6):700-6 [7777355.001]
  • [Cites] J Laryngol Otol. 1990 Apr;104(4):350-1 [2370460.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Jul-Aug;64(4):297-9 [12232480.001]
  • [Cites] Am J Otolaryngol. 1996 Mar-Apr;17(2):102-5 [8820184.001]
  • (PMID = 18066514.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 28
  •  go-up   go-down


11. Boccon-Gibod L, Boman F, Josset P, Landman-Parker J: Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Jun 15;44(7):673-5
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia.
  • Occurrence of second cancers is a major concern for the care of children cured of cancer.
  • Children treated for acute lymphoblastic leukemia (ALL) have an increased risk for developing mucoepidermoid carcinomas (MEC) of the parotid gland.
  • Treatment included multidrug chemotherapy and prophylactic intrathecal injections of methotrexate and prednisolone.
  • Low-grade MEC of the left parotid gland was diagnosed at the age of 7 years, only 1 year after completing treatment.
  • This case report is remarkable for the early diagnosis of second cancer, only 4 years after diagnosis of ALL, and its occurrence in parotid gland without previous head and neck irradiation.
  • It highlights the need for concern about second cancers of the parotid gland in children treated for ALL.
  • [MeSH-major] Carcinoma, Mucoepidermoid / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15515042.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


12. Bradley P, McClelland L, Mehta D: Paediatric salivary gland epithelial neoplasms. ORL J Otorhinolaryngol Relat Spec; 2007;69(3):137-45
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric salivary gland epithelial neoplasms.
  • Salivary gland epithelial neoplasms in children are rare.
  • Clinicians of all disciplines need to have a high level of suspicion when a non-inflammatory single mass lesion presents in the parotid or submandibular glands.
  • Surgery is the primary treatment of choice in the majority of cases, with the addition of adjuvant radiotherapy +/- chemotherapy when the diagnosis is a high-grade tumour and/or when the malignancy presents as a large mass or is associated with local tissue invasion.
  • Minor salivary gland neoplasms also present, the oral cavity is most frequent, with pleomorphic adenoma and mucoepidermoid carcinoma being most common, other malignant neoplasms have been reported in other sites.
  • [MeSH-major] Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Carcinoma / classification. Carcinoma / pathology. Carcinoma / surgery. Child. Child, Preschool. Epithelium / pathology. Humans. Infant. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17264529.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 46
  •  go-up   go-down


13. Oudidi A, El-Alami MN, Boulaich M, Jazouli N, Kzadri M: [Primary sub-mandibular gland tumours: experience based on 68 cases]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):187-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary sub-mandibular gland tumours: experience based on 68 cases].
  • [Transliterated title] Les tumeurs primitives de la glande sous-maxillaire: à propos de 68 cas.
  • Sub-mandibulary gland tumours are less common than tumours of the parotid and pose many clinical and therapeutic challengers.
  • PATIENTS AND METHODS: Retrospective studies of sub-mandibular gland tumours presenting to our department between 1986 and 2000.
  • RESULTS: 68 cases were reviewed comprising 37 benign and 31 malignant tumours (15 females and 33 males).
  • CAT Scans were performedd to assess tumour extent / invasion.
  • Definitive diagnosis was by complete excision and pathological examination.
  • For malignant lesions (n= 31) the most frequent were: Adenoid cystic carcinoma (n= 10), epidermoid carcinoma (n= 5), adenocarcinoma (n= 5), mucoepidermoid carcinoma (n= 3), malignant non Hodgkinien lymphoma (n= 5).
  • Treatment was by total surgical excision of the submandibular gland for the begnin tumours.
  • For the malignant lesions it was associated acording to their extension with other anatomical region or in case of adenopathy with neck dissection.
  • Radiotherapy was performed in 24 cases and chemotherapy in 10 cases.
  • CONCLUSION: Malignity in sub-mandibular gland tumours is more frequent than in the parotid gland.
  • Any delay in diagnosis or inappropriate management may result in a poor prognosis for the patient.
  • [MeSH-major] Submandibular Gland Neoplasms / classification. Submandibular Gland Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Early Diagnosis. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007195.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Ezeanolue BC: Residual and recurrent parotid gland neoplasm after surgical excision. West Afr J Med; 2002 Jan-Mar;21(1):5-8
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual and recurrent parotid gland neoplasm after surgical excision.
  • Ten patients who presented with residual or recurrent parotid gland neoplasm after elective curative surgical excision between January 1992 to December 1999 were studied.
  • It aimed at finding the contributory factors responsible for the persistence or recurrence of the tumour after surgical excision.
  • Seven were of malignant histologic cell types while three were benign.
  • Eight patients were treated with secondary parotidectomy while two received combination chemotherapy.
  • In five patients, both the superficial and deep lobes of the parotid gland were found during secondary parotidectomy.
  • Four patients were later referred to radiotherapy centers for further treatment It is concluded that most recurrent parotid neoplasm is a result of inadequate primary surgical excision, and best results are obtained by doing a minimum of superficial parotidectomy in the surgical treatment of parotid gland neoplasms.
  • [MeSH-major] Neoplasm Recurrence, Local / etiology. Parotid Neoplasms / surgery. Surgical Procedures, Operative / standards
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Prospective Studies. Retrospective Studies. Thyroidectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12081344.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


15. Charabi S, Balle V, Charabi B, Nielsen P, Thomsen J: Surgical outcome in malignant parotid tumours. Acta Otolaryngol Suppl; 2000;543:251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in malignant parotid tumours.
  • Of 494 parotid gland tumours treated in Copenhagen county (population 600,000 inhabitants) in the period 1986-95, 50 patients (34 males, 16 females) had tumours that were proven to be malignant, making an incidence of 0.62/100,000/year.
  • The material included 41 primary parotid gland tumours, histologically the tumours were verified as mucoepidermoid carcinoma (n = 13), adenocarcinoma (n = 9), squamous cell carcinoma (n = 6), carcinoma ex pleomorph adenoma (n = 3), acinic cell carcinoma (n = 3), adenoid cystic carcinoma (n = 3) and other histological diagnoses (n = 4).
  • Primary malignant lymphoma of the parotid gland was diagnosed in six tumours and the last three tumours were metastatic carcinoma.
  • Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation.
  • Surgical radicality was achieved in 76% and radicality was unrelated to tumour histology.
  • No significant difference was observed in 5-year crude survival or in the post-operative facial nerve function between the radically operated patients (n = 38) and patients with residual tumour (p = 0.27, Log-rank test), (p = 0.48, chi 2 test).
  • [MeSH-major] Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Combined Modality Therapy. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10909035.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


16. Macák J, Smardová J, Zavrelová I, Vránová V, Kuglík P: Malignant fibrous histiocytoma of the parotid gland. Cesk Patol; 2007 Oct;43(4):148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the parotid gland.
  • We described a rare malignant fibrous histiocytoma of the parotid gland (MFH) in a 63-year-old woman.
  • During six months the tumour size became 10 cm in diameter with skin ulceration.
  • The tumour was examined morphologically, by immunohistochemistry and molecular biology methods - FASAY and CGH.
  • The histology revealed a storiform-pleomorphic type of MFH with high mitotic rate.
  • The chromosomal changes were identified by the CGH method and 6 cytogenetic changes were found in the tumour cells (deletions at 8p12-p22, 13q32-qter, 14q24-qter, and gains of chromosomal material at 5p, 8q12-q23, and Xq25-qter).
  • The patient died shortly after the beginning of chemotherapy.
  • No other tumour foci were proved.
  • In view of short course of disease we lack the data about the influence of the non-mutated p53 gene on the prognosis and therapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188922.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


17. Obaid MA, Yusuf A: Surgical management of epithelial parotid tumours. J Coll Physicians Surg Pak; 2004 Jul;14(7):394-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of epithelial parotid tumours.
  • OBJECTIVE: To describe the clinicopathological presentation and treatment options in epithelial parotid tumours with emphasis on surgery.
  • SUBJECTS AND METHODS: Epithelial parotid tumours diagnosed and operated by an ENT surgeon and a general surgeon in 10 years during their posting in different teaching hospitals were included in the study.
  • Clinical presentation, preoperative investigations, operative procedure, histopathology report, postoperative complications and further management were recorded.
  • RESULTS: Fifty-two patients presented with parotid tumour.
  • Commonest presentation was a painless lump over the parotid region (85%), pain (15%), facial palsy, and enlarged neck nodes.
  • Parotid pleomorphic Adenoma (PPA) was the commonest benign tumour, others being Warthin's tumour and monomorphic adenoma.
  • Adenoid cystic carcinoma was the commonest malignant tumour 29% followed by mucoepidermoid carcinoma.
  • Others were carcinoma in PPA, squamous cell carcinoma, malignant mixed tumour, malignant lymphoepithelioma and undifferentiated carcinoma.
  • Except for one child, rest of the 13 patients received postoperative radiotherapy and one patient of lymphoepithelioma received chemotherapy in addition.
  • Of these 07 had a malignant process and only one patient had excision biopsy.
  • CONCLUSION: Benign and malignant epithelial parotid tumours can be diagnosed by their clinical presentation supplemented with FNAC.
  • Facial nerve can be saved in total conservative parotidectomy for benign tumour in deep lobe and early malignant tumour.
  • Radical parotidectomy followed by radiotherapy and in selected cases neck node dissection are the recommended procedures for advanced malignant parotid tumours.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Parotid Gland / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / surgery. Postoperative Complications. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279739.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


18. Laskawi R, Ellies M: The role of botulinum toxin in the management of head and neck cancer patients. Curr Opin Otolaryngol Head Neck Surg; 2007 Apr;15(2):112-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of botulinum toxin in the management of head and neck cancer patients.
  • PURPOSE OF REVIEW: In this review article different relevant applications of botulinum toxin type A are demonstrated in patients with head and neck cancer.
  • RECENT FINDINGS: Patients with head and neck cancers of different etiologies often suffer from disorders concerning their musculature (for example, synkinesis in mimic muscles) or gland secretion in the head and neck region.
  • The application of botulinum toxin type A can improve movement disorders like synkinesis following reconstructive surgery in patients with cancers of the parotid gland, spasms of the pharyngo-esophageal musculature following laryngectomies and disorders of the autonomous nerve system like hypersalivation, hyperlacrimation and pathological sweating.
  • SUMMARY: The application of botulinum toxin type A is a helpful and minimally invasive treatment option in different functional disorders improving the quality of life in patients with head and neck cancers of different etiologies.
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Head and Neck Neoplasms / complications. Neuromuscular Agents / therapeutic use
  • [MeSH-minor] Dyskinesias / drug therapy. Dyskinesias / etiology. Facial Nerve Injuries / complications. Facial Nerve Injuries / etiology. Facial Paralysis / drug therapy. Facial Paralysis / etiology. Humans. Lacrimal Apparatus Diseases / drug therapy. Lacrimal Apparatus Diseases / etiology. Laryngectomy / adverse effects. Muscle Spasticity / complications. Muscle Spasticity / drug therapy. Muscle Spasticity / etiology. Sialorrhea / drug therapy. Sialorrhea / etiology. Speech Disorders / drug therapy. Speech Disorders / etiology. Sweating, Gustatory / drug therapy. Sweating, Gustatory / etiology

  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413413.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 20
  •  go-up   go-down


19. Palma S, Cavazzini L, Bovo R, Padovani D, Bugli AM, Borrelli M, Martini A: Merkel cell tumour of the external ear. Report of a case. Auris Nasus Larynx; 2007 Jun;34(2):229-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumour of the external ear. Report of a case.
  • MCC is often an aggressive tumour with high tendency for local recurrence, lymph node involvement and distant metastasis.
  • The authors report a case of the ear canal characterized by two others synchronous tumours and the occurrence of a malignant high grade lymphoma, in which contribute of the pathologist was essential for a critical review.
  • MCC diagnosis is not always easy for its pathological and clinical features and it should always be considered in presence of lymphoma.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Ear Neoplasms / diagnosis. Ear, External
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Fatal Outcome. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Humans. Keratins / analysis. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Magnetic Resonance Imaging. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Parotid Gland / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064866.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


20. Markowski J, Gierek T, Zielińska-Pajak E, Witkowska M, Wodołazski A, Pajak J, Paluch J: [Distant metastases to the parotid gland--review of the literature and report of own two cases]. Otolaryngol Pol; 2005;59(4):547-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases to the parotid gland--review of the literature and report of own two cases].
  • Metastatic tumors to the parotid gland are very uncommon and it accounts for 8% of all cancers of parotid gland.
  • The parotid gland and its lymph nodes are possible sites of metastases from head and neck cancers.
  • However, metastasis from distant primary neoplasm below clavicle is possible, too.
  • The authors presented the two cases of distant metastases to the parotid gland.
  • The women with breast cancer and metastases to the parotid gland 11 years after surgery, radio- and chemotherapy of breast cancer.
  • She died 7 months after parotid surgery of systemically advanced disease.
  • The man with metastasis of malignant melanoma of unknown primary site.
  • He underwent total parotid surgery with the tumor and lymph nodes.
  • The authors described pathophysiology of distant metastases to the parotid gland with special attention to possibilities of treatment and survival.
  • [MeSH-major] Breast Neoplasms / pathology. Melanoma / pathology. Neoplasms, Unknown Primary / genetics. Neoplasms, Unknown Primary / pathology. Parotid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273860.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 15
  •  go-up   go-down


21. Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R: Major and minor salivary glands tumours. Crit Rev Oncol Hematol; 2003 Feb;45(2):215-25
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant salivary gland tumours are rare.
  • The most common tumour site is the parotid.
  • Nutrition may be a risk factor, as well as irradiation or an histologically benign tumour occurred at a young age.
  • Painless swelling of a salivary gland should always be considered as suspicious, especially if no sign of inflammation is present.
  • Signs and symptoms related to major salivary gland tumours differ from those concerning minor salivary gland tumours, as they depend on the different location of the salivary gland.
  • Surgical excision represents the standard option in the treatment of resectable tumours of both major and minor salivary glands.
  • Neutron radiation may be a treatment option for inoperable locoregional disease.
  • Surgery, irradiation or re-irradiation are treatment options for local relapse, whereas radical neck dissection is indicated for regional relapses.
  • Metastastic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases.
  • [MeSH-major] Salivary Gland Neoplasms
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12604131.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 51
  •  go-up   go-down


22. Kempf VA, Petzold H, Autenrieth IB: Cat scratch disease due to Bartonella henselae infection mimicking parotid malignancy. Eur J Clin Microbiol Infect Dis; 2001 Oct;20(10):732-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cat scratch disease due to Bartonella henselae infection mimicking parotid malignancy.
  • An unusual Bartonella henselae infection presenting clinically as a putative parotid cancer was diagnosed based on serological tests, histomorphology and amplification of a 16S-rDNA sequence of Bartonella henselae.
  • The patient improved greatly upon antibiotic treatment and did not require surgery.
  • Although uncommon, infection with Bartonella spp., particularly Bartonella henselae, should be included in the differential diagnosis of parotid tumors.
  • [MeSH-major] Bartonella henselae / isolation & purification. Cat-Scratch Disease / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents. Biopsy, Needle. Blotting, Western. Diagnosis, Differential. Drug Therapy, Combination / therapeutic use. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Cat Scratch Disease.
  • MedlinePlus Health Information. consumer health - Cat Scratch Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757975.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down






Advertisement